Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update

Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Holdaas, Hallvard, De Simone, Paolo, Zuckermann, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078653/
https://www.ncbi.nlm.nih.gov/pubmed/27807479
http://dx.doi.org/10.1155/2016/4369574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078653/
https://www.ncbi.nlm.nih.gov/pubmed/27807479
http://dx.doi.org/10.1155/2016/4369574

Ejemplares similares